PL3116902T3 - Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznego - Google Patents
Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznegoInfo
- Publication number
- PL3116902T3 PL3116902T3 PL15709185T PL15709185T PL3116902T3 PL 3116902 T3 PL3116902 T3 PL 3116902T3 PL 15709185 T PL15709185 T PL 15709185T PL 15709185 T PL15709185 T PL 15709185T PL 3116902 T3 PL3116902 T3 PL 3116902T3
- Authority
- PL
- Poland
- Prior art keywords
- generating
- allogenic transplantation
- cells compatible
- compatible
- cells
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201470119 | 2014-03-11 | ||
PCT/EP2015/055097 WO2015136001A1 (en) | 2014-03-11 | 2015-03-11 | Method for generating t-cells compatible for allogenic transplantation |
EP15709185.1A EP3116902B1 (en) | 2014-03-11 | 2015-03-11 | Method for generating t-cells compatible for allogenic transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3116902T3 true PL3116902T3 (pl) | 2020-07-27 |
Family
ID=50336023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15709185T PL3116902T3 (pl) | 2014-03-11 | 2015-03-11 | Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznego |
Country Status (17)
Country | Link |
---|---|
US (3) | US20170016025A1 (pl) |
EP (3) | EP4368705A2 (pl) |
JP (2) | JP6681837B2 (pl) |
KR (1) | KR102228828B1 (pl) |
CN (1) | CN106103475B (pl) |
AU (1) | AU2015228844B2 (pl) |
BR (1) | BR112016019071A8 (pl) |
CA (1) | CA2942113C (pl) |
DK (2) | DK3116902T3 (pl) |
ES (1) | ES2782125T3 (pl) |
HU (1) | HUE048558T2 (pl) |
IL (1) | IL247064B (pl) |
MX (1) | MX2016010923A (pl) |
PL (1) | PL3116902T3 (pl) |
PT (2) | PT3116902T (pl) |
RU (1) | RU2752933C2 (pl) |
WO (1) | WO2015136001A1 (pl) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
LT3066201T (lt) | 2013-11-07 | 2018-08-10 | Editas Medicine, Inc. | Su crispr susiję būdai ir kompozicijos su valdančiomis grnr |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
KR102228828B1 (ko) | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
KR20230152175A (ko) * | 2014-04-18 | 2023-11-02 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
JP2017524348A (ja) * | 2014-06-10 | 2017-08-31 | モナッシュ ユニバーシティ | 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法 |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
CN107208055B (zh) * | 2015-01-17 | 2021-06-15 | 浙江大学 | 引起免疫原性反应降低的被修饰细胞 |
BR112017015453A2 (pt) | 2015-01-26 | 2018-01-23 | Cellectis | células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
CA2998894A1 (en) * | 2015-09-18 | 2017-03-23 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
DK3680329T3 (da) | 2015-10-05 | 2021-08-23 | Prec Biosciences Inc | Modificerede meganukleaser med genkendelsesekvenser der findes i genet for den humane t-cellereceptor-alpha-konstantregion |
CN108601821B (zh) | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
WO2017070633A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
BR112018011089A2 (pt) * | 2015-12-04 | 2018-12-04 | Intellia Therapeutics Inc | composições e métodos para a imuno-oncologia |
CA3008413A1 (en) * | 2015-12-18 | 2017-06-22 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
CA3008382A1 (en) | 2015-12-18 | 2017-06-22 | Sangamo Therapeutics, Inc. | Targeted disruption of the mhc cell receptor |
ES2901000T3 (es) * | 2015-12-23 | 2022-03-21 | Prec Biosciences Inc | Meganucleasas de ingeniería con secuencias de reconocimiento encontradas en el gen de la microglobulina beta-2 humana |
AU2017226172B9 (en) * | 2016-03-04 | 2023-08-24 | Editas Medicine, Inc. | CRISPR/Cpf1-related methods, compositions and components for cancer immunotherapy |
US10894093B2 (en) | 2016-04-15 | 2021-01-19 | Cellectis | Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
CN109414512A (zh) * | 2016-04-22 | 2019-03-01 | 科济生物医药(上海)有限公司 | 用于细胞免疫疗法的组合物和方法 |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
EP3519433A1 (en) | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
CA3039928A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
CN110520530A (zh) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
EP3529265A2 (en) * | 2016-10-19 | 2019-08-28 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
AU2018208614A1 (en) * | 2017-01-10 | 2019-07-11 | The General Hospital Corporation | Modified T cells and methods of their use |
CN107058230B (zh) * | 2017-01-20 | 2020-03-24 | 山东兴瑞生物科技有限公司 | 一种沉默t细胞抗原受体的t淋巴细胞的制备方法 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11851659B2 (en) * | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
MX2019011475A (es) | 2017-03-31 | 2019-12-16 | Cellectis | Celulas inmunes universales manipuladas para ser dotadas con receptor de antigeno quimerico anti-cd22. |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
EP4029943A1 (en) * | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
KR20200005596A (ko) | 2017-05-12 | 2020-01-15 | 크리스퍼 테라퓨틱스 아게 | 세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도 |
CA3064597A1 (en) * | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
CN110914409A (zh) * | 2017-06-13 | 2020-03-24 | 菲特治疗公司 | 用于诱导骨髓抑制细胞的组合物和方法以及其用途 |
JP7419073B2 (ja) * | 2017-06-16 | 2024-01-22 | サンガモ セラピューティクス, インコーポレイテッド | T細胞および/またはhla受容体の標的化破壊 |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
AU2018292526A1 (en) | 2017-06-30 | 2020-01-16 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
US20190004063A1 (en) * | 2017-06-30 | 2019-01-03 | Indiana University Research & Technology Corporation | Compositions and methods for detecting sla reactivity |
EP3640333A4 (en) * | 2017-07-14 | 2020-12-30 | Cure Genetics Co., Ltd | GENE EDITING SYSTEM AND GENE EDITING METHOD |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
EP3680338A4 (en) * | 2017-09-08 | 2021-06-02 | Carsgen Therapeutics Co., Ltd. | GENETICALLY MODIFIED LYMPHOCYTE T AND ITS APPLICATION |
SG11202002728VA (en) | 2017-10-03 | 2020-04-29 | Juno Therapeutics Inc | Hpv-specific binding molecules |
WO2019071009A2 (en) * | 2017-10-05 | 2019-04-11 | Nantcell, Inc. | LIPID ANTIGENS AND L-CELL RECEPTORS ON NK CELLS |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
CA3084476A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | Targeted gene integration of nk inhibitors genes for improved immune cells therapy |
CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
CN109694854B (zh) * | 2017-10-20 | 2023-11-21 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
WO2019097083A1 (en) * | 2017-11-20 | 2019-05-23 | Tessa Therapeutics Pte. Ltd. | Modified k562 cell |
CN112236514A (zh) * | 2017-12-05 | 2021-01-15 | 塞利亚德股份公司 | 改善细胞过继转移的持久性的组合物和方法 |
SG11202003864XA (en) * | 2017-12-13 | 2020-07-29 | Janssen Biotech Inc | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響トランスデューサドライバ及びコントローラ |
US11227325B1 (en) | 2017-12-18 | 2022-01-18 | Wells Fargo Bank, N.A. | Event-based automatic transaction system |
EP3757133A4 (en) * | 2018-02-11 | 2021-12-01 | Jiangsu Hengrui Medicine Co., Ltd. | ISOLATED CHIMERIC ANTIGEN RECEPTOR, THIS MODIFIED T-CELL CONTAINED AND USES |
US20210040449A1 (en) * | 2018-02-16 | 2021-02-11 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
US20200407693A1 (en) * | 2018-02-16 | 2020-12-31 | Kyoto University | Method for producing low-antigenic cell |
US20210015869A1 (en) | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
MA52193A (fr) | 2018-04-05 | 2021-02-17 | Juno Therapeutics Inc | Récepteurs de lymphocytes t et cellules modifiées les exprimant |
EP3774871B1 (en) | 2018-04-12 | 2023-06-28 | Precision BioSciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
WO2019204664A2 (en) * | 2018-04-19 | 2019-10-24 | Apdn (B.V.I), Inc. | Engineered lymphocyte compositions, methods and systems |
SG11202009626QA (en) | 2018-04-20 | 2020-10-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
SG11202010319RA (en) | 2018-04-27 | 2020-11-27 | Iovance Biotherapeutics Inc | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
AU2019260804A1 (en) * | 2018-04-27 | 2020-11-12 | Bayer Healthcare Llc | Methods and compositions of cytotoxic T cell depletion |
EP3790629A1 (en) * | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
US20220017926A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | Method for gene editing of cell on the basis of crispr/cas system |
CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
KR20210089712A (ko) * | 2018-11-07 | 2021-07-16 | 크리스퍼 테라퓨틱스 아게 | 항-cd33 면역세포 암 치료법 |
CA3118824A1 (en) * | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
CN111349606A (zh) * | 2018-12-20 | 2020-06-30 | 上海恒润达生生物科技有限公司 | P60抑制剂与cart细胞联合应用 |
EP3908665A4 (en) * | 2019-01-07 | 2022-10-12 | The Regents of the University of California | SYNTHETIC MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE |
CN109706121A (zh) * | 2019-01-25 | 2019-05-03 | 苏州茂行生物科技有限公司 | 一种基于碱基编辑的通用型car-t细胞及其制备方法和应用 |
KR20210138603A (ko) * | 2019-02-13 | 2021-11-19 | 빔 테라퓨틱스, 인크. | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기를 갖는 변형된 면역 세포 |
AU2020226893A1 (en) * | 2019-02-21 | 2021-09-23 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
CN113766956B (zh) | 2019-03-05 | 2024-05-07 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
KR20210148293A (ko) | 2019-04-03 | 2021-12-07 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
TW202115245A (zh) * | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
WO2020259707A1 (zh) * | 2019-06-28 | 2020-12-30 | 科济生物医药(上海)有限公司 | 抗移植反应的细胞和方法 |
JP2024500254A (ja) * | 2019-08-29 | 2024-01-09 | クレージュ メディカル カンパニー,リミテッド | 移植拒絶反応に抵抗する細胞及び方法 |
JP2022547053A (ja) * | 2019-09-05 | 2022-11-10 | クリスパー セラピューティクス アクチェンゲゼルシャフト | ユニバーサルドナー細胞 |
CA3150235A1 (en) * | 2019-09-05 | 2021-03-11 | Alireza Rezania | UNIVERSAL DONOR CELLS |
CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021091935A1 (en) * | 2019-11-05 | 2021-05-14 | Lonza Walkersville, Inc. | Allogeneic t-cells and methods for production thereof |
JPWO2021106832A1 (pl) * | 2019-11-25 | 2021-06-03 | ||
CN115175928A (zh) | 2019-12-23 | 2022-10-11 | 塞勒克提斯公司 | 用于实体瘤癌症免疫疗法的新型间皮素特异性嵌合抗原受体(car) |
US20210254005A1 (en) * | 2020-01-23 | 2021-08-19 | Kangstem Biotech Co., Ltd. | Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same |
WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
WO2021216978A1 (en) * | 2020-04-23 | 2021-10-28 | Aztherapies, Inc. | Cellular ablation of hla-class i mhc |
KR20230019843A (ko) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물 |
CN116234558A (zh) | 2020-06-26 | 2023-06-06 | 朱诺治疗学有限公司 | 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法 |
EP4176261A1 (en) | 2020-07-03 | 2023-05-10 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
WO2022007784A1 (en) * | 2020-07-06 | 2022-01-13 | Nanjing Legend Biotech Co., Ltd. | Methods of reducing graft rejection of allogeneic cell therapy |
KR20220005208A (ko) * | 2020-07-06 | 2022-01-13 | 주식회사 지씨셀 | 면역원성이 감소된 신규한 이식용 세포 |
EP4185616A1 (en) | 2020-07-24 | 2023-05-31 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
JP2023536820A (ja) | 2020-07-31 | 2023-08-30 | セレクティス ソシエテ アノニム | 二重car-t細胞 |
JP2023538116A (ja) * | 2020-08-20 | 2023-09-06 | エー2 バイオセラピューティクス, インコーポレイテッド | Egfr陽性がんを治療するための組成物及び方法 |
CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
CN114525259A (zh) * | 2020-11-03 | 2022-05-24 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
CN114657137A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
JP2024506557A (ja) | 2021-01-29 | 2024-02-14 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用 |
WO2022171179A1 (zh) | 2021-02-10 | 2022-08-18 | 苏州克睿基因生物科技有限公司 | 一种扩增增强子及其应用 |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
AR125199A1 (es) | 2021-03-23 | 2023-06-21 | Iovance Biotherapeutics Inc | Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia |
KR20240007179A (ko) | 2021-04-30 | 2024-01-16 | 셀렉티스 에스.에이. | 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포 |
EP4340850A1 (en) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3218475A1 (en) | 2021-05-21 | 2022-11-24 | Shipra DAS | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
CN117858943A (zh) * | 2021-08-24 | 2024-04-09 | 赛斯尔擎生物技术(上海)有限公司 | T细胞产品及其用途 |
AU2022343108A1 (en) * | 2021-09-10 | 2024-03-21 | Kite Pharma, Inc. | Alternative generation of allogeneic human t cells |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023151620A1 (zh) * | 2022-02-09 | 2023-08-17 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
WO2023183434A2 (en) * | 2022-03-22 | 2023-09-28 | Artisan Development Labs, Inc. | Compositions and methods for generating cells with reduced immunogenicty |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023201340A2 (en) * | 2022-04-15 | 2023-10-19 | The General Hospital Corporation | Compositions and methods for reducing cell therapy immunogenicity |
CN117004604A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种ciita基因被敲除的工程化免疫细胞及其用途 |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
EP4282963A1 (en) | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
CN114958768B (zh) * | 2022-06-02 | 2023-03-24 | 健颐生物科技发展(山东)有限公司 | Fgf10旁分泌通用型人成纤维细胞制剂的制备方法 |
WO2024003334A1 (en) | 2022-06-30 | 2024-01-04 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
CA2113089C (en) * | 1991-07-15 | 2007-11-06 | Peter J. Sims | Universal donor cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
US20060222633A1 (en) * | 2000-05-11 | 2006-10-05 | Yale University | Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host |
KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Rna 간섭을 매개하는 작은 rna 분자 |
EP2360251B1 (en) | 2001-07-12 | 2016-09-28 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US9982251B2 (en) | 2003-03-14 | 2018-05-29 | Cellectis S.A. | Large volume ex vivo electroporation method |
DE602005015302D1 (en) * | 2004-04-05 | 2009-08-20 | Univ California | Nkg2d modulation |
ES2347684T3 (es) | 2005-03-15 | 2010-11-03 | Cellectis | Variantes de la meganucleasa i-crei con especificidad modifica, metodo de preparacion y usos de las mismas. |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
WO2008102199A1 (en) * | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
FR2931485B1 (fr) | 2008-05-23 | 2011-06-17 | Centre Nat Rech Scient | Vaccin antitumoral comprenant des cellules tumorales modifiees |
CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
ES2728436T3 (es) | 2011-04-05 | 2019-10-24 | Cellectis | Método para la generación de TALE-nucleasas compactas y usos de la mismas |
US20140134195A1 (en) | 2011-04-20 | 2014-05-15 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
TWI614340B (zh) * | 2011-09-28 | 2018-02-11 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
PT2838548T (pt) * | 2012-04-17 | 2023-10-13 | Univ Washington Through Its Center For Commercialization | Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas |
PL2855667T3 (pl) | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
EP2877488B1 (en) | 2012-07-24 | 2021-02-24 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
EP2964253A1 (en) | 2013-03-05 | 2016-01-13 | Baylor College Of Medicine | Heparanase expression in human t lymphocytes |
WO2014159435A1 (en) | 2013-03-14 | 2014-10-02 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified t cells |
US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
PT2981607T (pt) * | 2013-04-03 | 2020-11-20 | Memorial Sloan Kettering Cancer Center | Geração eficaz de células t direcionadas a tumores, derivadas de células estaminais pluripotentes |
CN105518146B (zh) * | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
WO2015037760A1 (ko) | 2013-09-13 | 2015-03-19 | 볼보 컨스트럭션 이큅먼트 에이비 | 건설기계용 플로트 밸브 |
KR102228828B1 (ko) | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
JP2018509148A (ja) * | 2015-03-11 | 2018-04-05 | セレクティスCellectis | 患者における持続性および/または生着を増加させるために同種t細胞を改変する方法 |
US10322774B2 (en) * | 2015-05-15 | 2019-06-18 | Oru Designs, Llc | Collapsible kayak with large cockpit |
-
2015
- 2015-03-11 KR KR1020167028153A patent/KR102228828B1/ko active IP Right Grant
- 2015-03-11 PT PT157091851T patent/PT3116902T/pt unknown
- 2015-03-11 AU AU2015228844A patent/AU2015228844B2/en active Active
- 2015-03-11 DK DK15709185.1T patent/DK3116902T3/da active
- 2015-03-11 RU RU2016139643A patent/RU2752933C2/ru active
- 2015-03-11 PT PT192199545T patent/PT3693384T/pt unknown
- 2015-03-11 US US15/123,974 patent/US20170016025A1/en not_active Abandoned
- 2015-03-11 BR BR112016019071A patent/BR112016019071A8/pt active Search and Examination
- 2015-03-11 CN CN201580012829.6A patent/CN106103475B/zh active Active
- 2015-03-11 EP EP24153261.3A patent/EP4368705A2/en active Pending
- 2015-03-11 HU HUE15709185A patent/HUE048558T2/hu unknown
- 2015-03-11 DK DK19219954.5T patent/DK3693384T3/da active
- 2015-03-11 MX MX2016010923A patent/MX2016010923A/es active IP Right Grant
- 2015-03-11 EP EP15709185.1A patent/EP3116902B1/en active Active
- 2015-03-11 EP EP19219954.5A patent/EP3693384B1/en active Active
- 2015-03-11 ES ES15709185T patent/ES2782125T3/es active Active
- 2015-03-11 CA CA2942113A patent/CA2942113C/en active Active
- 2015-03-11 WO PCT/EP2015/055097 patent/WO2015136001A1/en active Application Filing
- 2015-03-11 JP JP2016556702A patent/JP6681837B2/ja active Active
- 2015-03-11 PL PL15709185T patent/PL3116902T3/pl unknown
-
2016
- 2016-08-02 IL IL247064A patent/IL247064B/en active IP Right Grant
-
2018
- 2018-09-21 US US16/138,908 patent/US11820996B2/en active Active
-
2020
- 2020-03-24 JP JP2020051964A patent/JP7105266B2/ja active Active
-
2023
- 2023-10-04 US US18/480,890 patent/US20240026376A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247064A0 (en) | A method for generating t cells suitable for allogeneic transplantation | |
IL250700B (en) | Methods for increasing cas9-mediated engineering efficiency | |
IL250132A0 (en) | A method to induce t-cell immunocytotherapy from stem cell potential | |
EP3137876C0 (en) | PERSONALIZED HAIR COLORING PROCESS | |
GB201406151D0 (en) | Method | |
GB201410262D0 (en) | Novel method | |
PT3107573T (pt) | Imunoterapia com il-12 visada ao cancro | |
PT3196196T (pt) | Método para a preparação de calcobutrol | |
GB201404617D0 (en) | Instant messaging | |
EP3338539A4 (en) | APPARATUS FOR TRANSPLANTING PLANTS | |
GB201404615D0 (en) | Instant messaging | |
GB201403470D0 (en) | Method | |
IL250275A0 (en) | Semi-continuous culture methods | |
GB201413581D0 (en) | Instant messaging | |
EP3165679A4 (en) | Method for slope improvement | |
GB201413512D0 (en) | Instant messaging | |
GB201413513D0 (en) | Instant messaging | |
SG11201608285WA (en) | Controls for implementing multiplex analysis methods | |
EP3115985A4 (en) | Diagram generating method | |
PL3107679T3 (pl) | Sposób cięcia | |
PL3161136T3 (pl) | Sposób wzbogacania mikropęcherzyków | |
PL3154334T3 (pl) | Sposób wykorzystania drobnego torfu | |
HU4622U (en) | Arrangement for enhanced generating biogas | |
GB201417170D0 (en) | Focusing method | |
GB201413535D0 (en) | Culture |